Drug profile

The FDA adverse-event record for Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7

24 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7. See the species affected, top reactions, and outcomes below.

24
adverse-event reports
8.3%
death-coded share
Horse
most-reported species
8
Fever - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
24
Total Reports
2
Deaths Reported
8.3%
Death Rate

Active Ingredients

Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7

Administration Routes

Intramuscular

Species Affected

Horse 24

Most Affected Breeds

Quarter Horse 7
Warmblood (unspecified) 4
Pony of the Americas 2
Morgan 2
Tennessee Walking Horse 2
Appaloosa 1
Horse (unknown) 1
Missouri Fox Trotting Horse 1
Arab 1
Hanovarian 1

Most Reported Reactions

Fever 8
Lack of efficacy - NOS 5
Colic 5
Other abnormal test result NOS 4
Lethargy (see also Central nervous system depression in Neurological) 4
Decreased appetite 3
Injection site swelling 3
Swollen limb 3
Weight loss 3
Facial swelling (see also 'Skin') 2
Injection site inflammation 2
Ataxia 2

Outcome Breakdown

Recovered/Normal
11 (45.8%)
Ongoing
8 (33.3%)
Outcome Unknown
3 (12.5%)
Died
1 (4.2%)
Euthanized
1 (4.2%)

Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7 Adverse Event Insights

24 reports name Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7; 2 recorded a death outcome (8.3% of reported events, not a population-level mortality rate). Active ingredient: Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7. Administration route: Intramuscular.

By species: Horse (24 reports). By breed: Quarter Horse (7), Warmblood (unspecified) (4), Pony of the Americas (2).

Leading clinical signs: Fever (8), Lack of efficacy - NOS (5), Colic (5), Other abnormal test result NOS (4). Outcome, 24 coded reports: Recovered/Normal leads at 45.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.